| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 33.165 | 45.608 | 47.352 | 7.403 | 0 | 16.713 | 0 | 0 | 9.335 | 62.371 |
| Total Income - EUR | 35.137 | 41.266 | 34.108 | 8.016 | 40.586 | 39.287 | 349.248 | 2.357.721 | 1.612.117 | 256.653 |
| Total Expenses - EUR | 33.896 | 39.879 | 33.035 | 7.751 | 18.159 | 38.047 | 349.237 | 2.357.718 | 1.612.101 | 256.653 |
| Gross Profit/Loss - EUR | 1.240 | 1.387 | 1.074 | 265 | 22.427 | 1.240 | 11 | 3 | 16 | 1 |
| Net Profit/Loss - EUR | 245 | 220 | 72 | 43 | 21.046 | 199 | 11 | 3 | 13 | 1 |
| Employees | 1 | 1 | 5 | 0 | 0 | 0 | 6 | 32 | 23 | 0 |
Check the financial reports for the company - Medacril S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 20.131 | 19.175 | 18.112 | 17.262 | 16.465 | 83 | 81 | 50.160 | 456.711 | 357.921 |
| Current Assets | 54.368 | 53.932 | 57.308 | 52.836 | 27.228 | 31.045 | 641.943 | 3.091.314 | 2.108.787 | 1.511.758 |
| Inventories | 37.120 | 32.257 | 21.830 | 21.861 | 7.426 | 3.796 | 352.370 | 1.367.753 | 1.275.902 | 711.609 |
| Receivables | 17.012 | 17.149 | 33.714 | 30.932 | 19.323 | 22.796 | 281.109 | 1.665.797 | 752.044 | 227.561 |
| Cash | 235 | 4.527 | 1.764 | 43 | 479 | 4.453 | 8.463 | 57.765 | 80.841 | 572.587 |
| Shareholders Funds | 789 | 1.001 | 1.056 | 1.079 | 22.104 | 31.125 | 30.446 | 30.544 | 30.464 | 30.295 |
| Social Capital | 67 | 67 | 66 | 64 | 63 | 9.303 | 9.097 | 9.125 | 9.097 | 9.046 |
| Debts | 73.710 | 72.106 | 74.365 | 69.019 | 21.589 | 2 | 352.386 | 1.465.323 | 1.813.969 | 1.839.384 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 259.191 | 1.645.607 | 721.065 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2016 - 2016" | |||||||||
| CAEN Financial Year |
2016
|
|||||||||
Comments - Medacril S.r.l.